title: Effects of bone marrow mononuclear cells from healthy or ovalbumin-induced lung inflammation donors on recipient allergic asthma mice.
abstract: BACKGROUND
  Asthma is characterized by a chronic inflammatory process which may lead to several changes in bone marrow cell composition. We hypothesized that bone marrow mononuclear cells (BMMCs) obtained from ovalbumin (OVA)-induced lung inflammation mice may promote different effects compared to BMMCs from healthy donors in a model of allergic asthma.
  
  
  METHODS
  C57BL/6 mice were randomly assigned to two groups. In the OVA group, mice were sensitized and challenged with ovalbumin, while healthy animals (control group) received saline using the same protocol. BMMCs were analyzed by flow cytometry 24 hours after the last challenge. After BMMC characterization, another group of OVA mice were further randomized into three subgroups to receive intratracheal saline (BMMC-SAL), BMMCs from control or BMMCs from OVA mice (BMMC-Control and BMMC-OVA, respectively; 2x10⁶ cells/mouse), 24 hours after the last challenge.
  
  
  RESULTS
  BMMC-OVA exhibited an increased percentage of eosinophils, monocytes and hematopoietic precursors, while mesenchymal stem cells decreased, as compared with BMMC-Control. BMMCs from both donor groups reduced airway resistance, alveolar collapse, bronchoconstriction index, eosinophil infiltration, collagen fiber content in alveolar septa and levels of interleukin (IL)-4, IL-5, IL-13, interferon-γ, transforming growth factor-β, and vascular endothelial growth factor in lung homogenates. However, the benefits of BMMCs were significantly more pronounced when cells were obtained from control donors.
  
  
  CONCLUSIONS
  Both BMMC-Control and BMMC-OVA reduced the inflammatory and remodeling processes; nevertheless, BMMC-Control led to a greater improvement in lung morphofunction, which may be due to different BMMC composition and/or properties.
authors.forename: Soraia C
authors.initials: SC
authors.lastname: Abreu
authors.forename: Mariana A
authors.initials: MA
authors.lastname: Antunes
authors.forename: Lucas
authors.initials: L
authors.lastname: Mendonça
authors.forename: Vivian C
authors.initials: VC
authors.lastname: Branco
authors.forename: Elga Bandeira
authors.initials: EB
authors.lastname: de Melo
authors.forename: Priscilla C
authors.initials: PC
authors.lastname: Olsen
authors.forename: Bruno L
authors.initials: BL
authors.lastname: Diaz
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weiss
authors.forename: Bruno D
authors.initials: BD
authors.lastname: Paredes
authors.forename: Debora G
authors.initials: DG
authors.lastname: Xisto
authors.forename: Marcelo M
authors.initials: MM
authors.lastname: Morales
authors.forename: Patricia R M
authors.initials: PR
authors.lastname: Rocco
mesh_terms: D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D001854:Bone Marrow Cells / Q000166:cytology; D016026:Bone Marrow Transplantation / Q000379:methods*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D004195:Disease Models, Animal; D005260:Female; D016130:Immunophenotyping; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000494:pharmacology; D011014:Pneumonia / Q000276:immunology / Q000473:pathology*; D011897:Random Allocation
chemical_list: D010047:Ovalbumin